27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
In this cohort study, high adherence to a flavonoid-rich diet score was associated with a lower risk of dementia, with reductions more pronounced in individuals with a high genetic risk, hypertension, and depressive symptoms. 5 key findings →
Design: cohort Participants: 121,986 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
After a median follow-up of 6.3 years, 678 individuals were diagnosed with dementia. 4 key findings →
Design: cohort Participants: 84,854 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A substantial proportion of the relationship between education and dementia was mediated through mid-life vascular risk factors. 2 key findings →
Design: cohort Participants: 13,368 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In the cohort analyses, 891 incident dementia cases were identified over 166,762 person-years. 4 key findings →
Design: meta-analysis Participants: 207,981 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The APOE epsilon4 allele is a genetic risk factor for dementia with stroke, including VaD and AD with CVD. 5 key findings →
Design: case-control study Participants: 187 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
At 48 months, group differences between clinical progressors and non-progressors were significant for self (2.13, SE=0.45, P Conclusions and relevance Demonstrating long-term clinical benefit will be critical for the success of recently launched secondary prevention trials. 1 key finding →
Design: longitudinal study Participants: 468 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Greater understanding of the risk factors and mechanisms of incident dementia in stroke survivors is needed for prevention and management. 3 key findings →
Design: longitudinal study Participants: 355 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We observed a complex series of relationships between social-environment variables and cognitive decline and dementia. 3 key findings →
Design: longitudinal study Participants: 2,854 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Intake of coffee alone or in combination with tea was associated with lower risk of poststroke dementia. 3 key findings →
Design: cohort study Participants: 365,682 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The acceleration of incidence rates for AD and dementia slows down with the increase in age, although we find no evidence of a rate decline. 2 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this large cohort, exposure to air pollution, even at the relative low levels, was associated with higher dementia incidence. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among well-functioning older adults, DM and poor glucose control among those with DM are associated with worse cognitive function and greater decline. 5 key findings →
Design: cohort study Participants: 717 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This review highlights that air pollutions, especially PM 2.5 and NO 2 play important role in the risk for age-related cognitive impairment and dementia. 3 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
We estimated the remaining lifetime risks of developing Alzheimer's disease (AD) and dementia from all causes, based on data from longitudinal population studies. 5 key findings →
Design: longitudinal study Participants: 198 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
SMI and EMCI with self-reported concerns were associated with the same risk of AD dementia, suggesting that pre-LMCI risk conditions should be extended to SMI with concerns. 5 key findings →
Design: cohort study Participants: 2,892 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Our cohort of 1,958,191 people from UK general practices had a median age at baseline of 55 years (IQR 45-66) and a median follow-up of 9·1 years (IQR 6·3-12·6). 4 key findings →
Design: cohort study Participants: 1,958,191 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Previously published community- or population-based studies of brain aging and dementia with autopsy were restricted to a single sex, a single ethnic group, Roman Catholic clergy, or focused pathological assessments. 2 key findings →
Design: longitudinal study Participants: 221 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Several studies report an association between REM Sleep Behavior Disorder (RBD) and neurodegenerative diseases, in particular synucleinopathies. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Retinal structures may serve as a biomarker for dementia, but longitudinal studies examining this link are lacking. 4 key findings →
Design: longitudinal study Participants: 5,065 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Central immunity components especially microglia in dementia have been well studied and corresponding immunotherapy gradually caught the attention. 4 key findings →
Design: longitudinal study Participants: 361,653 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dementia has been associated with COVID-19 prevalence, but whether this reflects higher infection, older age of patients, or disease severity remains unclear. 4 key findings →
Participants: 1,814 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We analyzed prospectively collected data in the Original and Offspring FHS cohorts. 4 key findings →
Design: case-control study Participants: 4,906 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Increasing evidence suggests an association between pro-inflammatory diets and cognitive function. 4 key findings →
Design: cohort study Participants: 1,372 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Grip strength and walking pace have been linked to cognitive dysfunction. 4 key findings →
Design: longitudinal study Participants: 340,212 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Data were drawn from the UK Biobank cohort study with a total of 228 223 participants with Hospital Episodes Statistics and primary care linkage health records. 4 key findings →
Design: cohort study Participants: 2,378 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
9 of the 1,130 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →